Bluebird Bio traded at $4.87 this Tuesday July 5th, increasing $0.59 or 13.67 percent since the previous trading session. Looking back, over the last four weeks, Bluebird Bio gained 63.26 percent. Over the last 12 months, its price fell by 84.32 percent. Looking ahead, we forecast Bluebird Bio to be priced at 4.16 by the end of this quarter and at 3.83 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
4.87
Daily Change
13.67%
Yearly
-84.32%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Agios Pharmaceuticals 24.78 1.42 6.08% -56.72%
Applied Genetic Technologies 0.80 0.02 2.99% -79.19%
Alnylam Pharmaceuticals 149.00 0.75 0.50% -14.56%
Amgen 244.20 -1.35 -0.55% 0.23%
Arrowhead Research 38.41 2.45 6.81% -39.10%
Avrobio Inc 0.93 0.01 1.25% -89.04%
Biogen 210.53 -0.10 -0.05% -38.96%
Bluebird Bio 4.87 0.59 13.67% -84.32%
BioMarin Pharmaceutical 85.19 0.21 0.25% 0.73%
Gilead Sciences 61.77 -0.59 -0.95% -9.71%
Intercept Pharmaceuticals 14.83 0.70 4.95% -22.11%
Immunogen 4.80 0.19 4.01% -23.28%
Incyte Corp 78.15 0.48 0.62% -6.23%
Ionis Pharmaceuticals 37.70 -0.36 -0.95% -4.14%
Moderna Inc 152.66 2.71 1.81% -34.58%
Mirati Therapeutics 70.85 -0.33 -0.46% -56.75%
Nektar Therapeutics 3.81 0.06 1.60% -77.47%
Novartis 80.91 -0.74 -0.91% -4.31%
Pfizer 50.98 -1.33 -2.54% 29.75%
PTC Therapeutics 42.20 0.35 0.84% -2.65%
Ultragenyx Pharmaceutical 63.32 0.67 1.06% -30.74%
Regeneron Pharmaceuticals 586.45 -8.95 -1.50% 0.72%
Seattle Genetics 176.60 -3.51 -1.95% 15.80%
Sangamo BioSciences 4.55 0.27 6.31% -59.56%
Sarepta Therapeutics 74.65 -1.06 -1.40% 1.94%
Vertex Pharmaceuticals 286.39 -0.93 -0.32% 43.16%

Indexes Price Day Year
USND 11195 67.56 0.61% -23.65%
US2000 1717 -10.96 -0.63% -24.52%

Bluebird Bio
bluebird bio, Inc. is a biotechnology company. The Company focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. It develops LentiGlobin for sickle cell disease (SCD) as a one-time treatment for patients with SCD, a hereditary blood disorder resulting from a mutation in the ß-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. It builds an integrated product platform with therapeutic in a variety of indications based on its lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. Its programs in genetic disease include betibeglogene autotemcel; LentiGlobin gene therapy for sickle cell disease (SCD); and elivaldogene autotemcel. Its programs in oncology are focused on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies.